Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
|Articles|November 14, 2022
Daily Dose: Remote Hypertension and Lipid Program
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On November 11, 2022, we reviewed a cohort study published in JAMA Cardiology that implemented and evaluated a remote hypertension (HTN) and cholesterol management program across a diverse health care network.
The study
Researchers recruited 10 803 participants aged between 26-80 years with blood pressure (BP) and/or cholesterol above guideline-recommended targets. Patient navigators were the primary point of contact with participants, responsible for all communications, collecting data, and conveying all recommendations made by the clinical team (eg, on diet, lifestyle, medication) in an effort to optimize risk reduction for adults. Participants received relevant education, integration of a home BP device, and guidance on medication titration from the patient navigator team.
The results
Among the participants in the HTN program who participated in remote medication management, the mean clinic SBP/DBP 6 months after enrollment decreased by 8.7/3.8 mm Hg and by 9.7/5.2 mm Hg at 12 months. Corresponding changes seen in the education-only group were a mean −1.5/−0.7 mm Hg at 6 months and +0.2/−1.9 mm Hg at 12 months (P <.001 for between cohort difference).
In the lipids program, patients who chose to receive remote medication management experienced a mean reduction in LDL-C of 35.4 mg/dL at 6 months and of 37.5 mg/dL at 12 months. Among those in the education-only cohort, mean reductions in LDL-C were 9.3 mg/dL and 10.2 mg/dL at 6 and 12 months, respectively (P<.001).
Clinical implications
"The findings in this study indicated an association between remote health delivery at scale and improvements in chronic disease metrics in a large urban and suburban outpatient cohort and across racial, ethnic, and language populations historically underserved by health care. We believe that this program may serve as a model for health care professionals and systems aiming to enhance access, patient engagement, and health outcomes."
Click here for the full study review.
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Advertisement
Advertisement